CatalYm GmbH

CatalYm GmbH is a biotechnology company developing visugromab, a monoclonal antibody designed to neutralize tumor-produced GDF-15, a key mediator of immune resistance to cancer therapies. GDF-15 is a protein that acts as an immunosuppressant, helping tumors evade the immune system and resist treatment. CatalYm's research has shown that blocking GDF-15 with visugromab can reverse this immunosuppression, allowing the immune system to more effectively target and destroy cancer cells.

CatalYm is currently conducting Phase 2 clinical trials of visugromab in combination with anti-PD-1 therapies for patients with advanced solid tumors. The company has also begun an exploratory Phase 2 study of visugromab in combination with neoadjuvant immunotherapy for patients with muscle-invasive bladder cancer. The company believes that visugromab has the potential to significantly improve outcomes for patients with solid tumors, particularly those who have not responded to existing therapies.

CatalYm GmbH is a biotechnology company focused on developing novel cancer immunotherapies. They are pioneering the reversal of GDF-15-mediated immunosuppression to induce a potent antitumoral immune reaction in non-responsive tumors. Their lead program, visugromab, a first-in-class GDF-15 neutralizing antibody, has demonstrated promising anti-tumor efficacy with long-lasting objective responses in combination with anti-PD-1 treatment in advanced cancer patients. CatalYm’s mission is to expand the treatment horizon for current and future immunotherapies by maximizing visugromab’s potential as a new class of cancer immunotherapy with a clinically distinct profile in a range of solid tumor indications.

CatalYm fosters a culture driven by scientific innovation and a strong entrepreneurial spirit. The company actively seeks individuals who are passionate about their work and committed to making a difference in cancer treatment. The leadership team, comprised of experienced professionals with a shared vision for advancing cancer immunotherapies, emphasizes collaboration and knowledge sharing, creating an environment where individuals can contribute their expertise and grow within the company. This collaborative approach is further reflected in their partnerships with renowned international researchers and investors.

CatalYm does not have information about diversity, equity and inclusion initiatives on its website. NONE